Close Menu

Gastrointestinal

News on in vitro diagnostics for gastrointestinal disease.

The study will recruit up to 200 patients with active Crohn's disease or ulcerative colitis and sort them into high- and low-risk cohorts using the PredictSure IBD test. 

The company's platform and assay use fluorescent lateral flow technology to detect Helicobacter pylori antigens in human stool samples.

Under the agreement, Theradiag will promote, license, and distribute PredictImmune's PredictSure IBD test in France, Belgium, Luxembourg, Switzerland, and the Maghreb countries. 

The device is intended for preparation of stool samples and use with Buhlmann's Fcal Turbo calprotectin test.

Progenity gains 137 granted patents and 15 pending applications in the US, Europe, China, and Japan in the deal.